| Term es nes pval sidak fdr geneset_size leading_edge leading_edge_size |
| Sphingolipid metabolism in senescence 0.715675034720198 2.458262538936267 0.0139611070457597 0.9997704638587088 0.7728347933180857 12 Q16739,P16278,Q13510,P04062,Q06136,Q96G23 6 |
| Degradation pathway of sphingolipids including diseases 0.8763865646044084 2.3901599023879734 0.0168410387249837 0.9999598440160324 0.7728347933180857 6 P06865,O43681,P17900,P06280 4 |
| Nanomaterial induced apoptosis 0.7535139208971635 2.3073501573557733 0.0210353074594951 0.9999968584126048 0.7728347933180857 8 O95831 1 |
| Glycosaminoglycan degradation 0.8478025310017419 2.2665749373714688 0.0234162045613461 0.9999992640129506 0.7728347933180857 6 P54802,P06865,P16278 3 |
| Sphingolipid pathway 0.6557904614477641 1.953767960156462 0.0507286650003067 0.9999999999999666 0.8085789099271942 10 Q16739,Q9Y5P4,Q13510,P04062,O15269,Q06136,Q96G23 7 |
| Disruption of postsynaptic signaling by cnv 0.6776881311827754 1.924698878180359 0.054267040934711 0.9999999999999964 0.8085789099271942 8 Q14168,Q06787 2 |
| Apoptosis modulation and signaling 0.573244135232707 1.9066515187755544 0.0565657289371186 0.9999999999999992 0.8222725474761637 16 O95831,Q9NR28 2 |
| Cellular proteostasis 0.8119062697910194 1.8765403304854256 0.060581122131154 1.0 0.8562541333026347 4 Q9UHV9,P61758,O15212 3 |
| Methionine de novo and salvage pathway 0.6615062276101403 1.84097091679709 0.0656258207765214 1.0 0.8578375061703493 8 Q13126 1 |
| Adipogenesis 0.5564976478767177 1.7986052347987551 0.0720811487097539 1.0 0.8578375061703493 16 Q9NZ45,P14174,O75844 3 |
| Triacylglyceride synthesis 0.7927363726073597 1.7938460676958063 0.0728377416694388 1.0 0.8578375061703493 4 Q9HCL2 1 |
| Pregnane x receptor pathway 0.7615053484337573 1.768732696932688 0.0769384930459171 1.0 0.8578375061703493 5 P08183 1 |
| Tcell antigen receptor tcr pathway during staphylococcus aureus infection 0.6453553897166276 1.7567129248373885 0.07896675337831 1.0 0.8578375061703493 8 P62993,O95433,Q12959,P49841,Q13153 5 |
| Sphingolipid metabolism overview 0.6436926229818568 1.7480002258983949 0.0804639883023115 1.0 0.8578375061703493 8 Q16739,Q13510,O15269,Q06136,Q96G23 5 |
| Sphingolipid metabolism integrated pathway 0.6436926229818568 1.7480002258983949 0.0804639883023115 1.0 0.8578375061703493 8 Q16739,Q13510,O15269,Q06136,Q96G23 5 |
| Metabolism of spingolipids in er and golgi apparatus 0.7701076630779013 1.695545374176597 0.089972010328998 1.0 0.8578375061703493 4 Q16739,Q06136,Q10472 3 |
| Mitochondrial complex iii assembly 0.6212092279233049 1.693629047048094 0.0903357948458367 1.0 0.8578375061703493 9 Q9UDW1,O14949,Q6DKK2 3 |
| Vitamin d receptor pathway 0.6016233405413267 1.6552486131197124 0.0978740778852076 1.0 0.8578375061703493 10 Q96KA5,Q92783,P08183 3 |
| Spinal cord injury 0.5390250498413047 1.586160374458176 0.1127029340791336 1.0 0.8838282725153114 20 Q9NQC3,P08670,P14174 3 |
| Proteoglycan biosynthesis 0.7107148769713494 1.540608017087711 0.1234122155475061 1.0 0.9286714730519948 5 Q8NCH0,Q9NX62 2 |
| Zinc homeostasis 0.7337535253600959 1.5362632478612672 0.1244738294180205 1.0 0.9286714730519948 4 Q8TAD4 1 |
| Hepatitis b infection 0.533244319230874 1.5242164362291466 0.1274546535092886 1.0 0.9286714730519948 21 Q07812,Q15750,Q15904,Q7Z434,P63104,P42574,O00571,P62993,P12004,P31946,P28482,Q9Y277,O00459,P51692 14 |
| Physicochemical features and toxicityassociated pathways 0.5295984706351522 1.4630441124795763 0.1434553088090933 1.0 0.9606670118002202 13 P62993,P28482,Q13153,P49841,P61158,P07196,P61160 7 |
| Genes related to primary cilium development based on crispr 0.6194726071220595 1.4099191702384437 0.1585635514370404 1.0 0.9822411846917544 7 A0AVF1,Q10713 2 |
| Ciliopathies 0.5055484512101819 1.3964783813853008 0.1625704862631605 1.0 0.9822411846917544 14 O43924,Q15555,Q10713 3 |
| Familial partial lipodystrophy fpld 0.5749210249217988 1.382098101997299 0.1669415811908279 1.0 0.9822411846917544 8 P51692,O60725,Q03252,O75844 4 |
| Estrogen receptor pathway 0.8258015601110504 1.376576784049844 0.1686431327102546 1.0 0.9822411846917544 3 Q9HCL2 1 |
| Striated muscle contraction pathway 0.6737408932530908 1.3726000929066973 0.169876703011051 1.0 0.9822411846917544 5 P28289,P08670,O43707,P67936 4 |
| Acquired partial lipodystrophy barraquersimons syndrome 0.6645375912050671 1.330613733769955 0.1833161411672912 1.0 0.9822411846917544 5 P20700,O60725,Q03252 3 |
| Oxidation by cytochrome p450 0.6604703821614862 1.3120449742385545 0.1895049603468104 1.0 0.9822411846917544 5 Q6UW02,O43169,Q16850 3 |
| Metapathway biotransformation phase i and ii 0.4984196664211123 1.2937649856393418 0.1957466105830554 1.0 0.9822411846917544 21 P07099,Q7LGA3,Q86UY6,P21964,Q16850,Q8NCH0 6 |
| Novel intracellular components of rigilike receptor rlr pathway 0.6340496229862365 1.2926890519118153 0.1961186258025482 1.0 0.9822411846917544 6 O00571 1 |
| 15q112 copy number variation syndrome 0.7898944517831749 1.2356243188589755 0.2165982407982292 1.0 1.0 3 Q9BSJ2 1 |
| Mammary gland development pathway pregnancy and lactation stage 3 of 4 0.6570837687423767 1.1970297709647275 0.2312949510968385 1.0 1.0 4 P61201,P06730 2 |
| Familial hyperlipidemia type 4 0.7748292979149809 1.1766001228865426 0.2393551487210192 1.0 1.0 3 Q9UBV2 1 |
| Allograft rejection 0.5150624539534343 1.1639468063124982 0.244445569434986 1.0 1.0 10 P08670,P08183 2 |
| Hostpathogen interaction of human coronaviruses mapk signaling 0.6259853496874326 1.1544830873904208 0.2483021684475912 1.0 1.0 5 P51812,P06730,Q15418 3 |
| Nitric oxide metabolism in cystic fibrosis 0.6457666909662021 1.146909738726705 0.2514189273040974 1.0 1.0 4 Q86X55,Q99873 2 |
| Cholesterol biosynthesis with skeletal dysplasias 0.6013211743580154 1.1384707258717848 0.2549239759961104 1.0 1.0 6 Q16850 1 |
| Nad metabolism 0.6431780929155486 1.1354557938547822 0.2561843938710209 1.0 1.0 4 P43490 1 |
| Il9 signaling pathway 0.5278164814060551 1.127016484792561 0.2597355112780382 1.0 1.0 8 P51692,P62993 2 |
| Bile acids synthesis and enterohepatic circulation 0.6317696867096732 1.0850400347814069 0.2779039241167589 1.0 1.0 4 P51114 1 |
| Nuclear receptors in lipid metabolism and toxicity 0.9310126582278476 1.0573985243133557 0.2903297447348234 1.0 1.0 2 P08183 1 |
| Overlap between signal transduction pathways contributing to lmna laminopathies 0.4405090048785079 1.0526786572763305 0.2924882935851969 1.0 1.0 15 P55209,O60725,P50402,O75844 4 |
| Hostpathogen interaction of human coronaviruses apoptosis 0.6241291956934725 1.051349069955724 0.2930982978559673 1.0 1.0 4 Q07812,P55210,Q07820 3 |
| Erk pathway in huntingtons disease 0.6241291956934634 1.051349069955683 0.2930982978559862 1.0 1.0 4 P28482,P42858,P55210 3 |
| Photodynamic therapyinduced nfe2l2 nrf2 survival signaling 0.919303797468354 1.0154391979803936 0.3098965160155056 1.0 1.0 2 P09601 1 |
| Eicosanoid synthesis 0.7331433998100617 1.0142847124221832 0.310446916614302 1.0 1.0 3 P09960,Q9H7Z7 2 |
| Aryl hydrocarbon receptor pathway wp2873 0.5723301626240114 1.0021225854422786 0.3162843909548434 1.0 1.0 6 Q16543 1 |
| Ferroptosis 0.4552159194497019 0.9827981744505307 0.3257067805177311 1.0 1.0 22 Q9UKU0,Q9Y277,P45880,Q9NZ45,P09601 5 |
| Inclusion body myositis 0.7198480531813836 0.9630145413982052 0.3355402258781783 1.0 1.0 3 P05067,Q92542 2 |
| Wnt signaling pathway and pluripotency 0.4310497250233019 0.9400010974609964 0.3472169977430548 1.0 1.0 17 P30154,P30153,P63151,Q9H0H5,P01130 5 |
| Progeriaassociated lipodystrophy 0.4693349614592853 0.9021400896732432 0.3669824550662808 1.0 1.0 10 O60725 1 |
| Mecp2 and associated rett syndrome 0.4388694593503773 0.8975693644519875 0.3694151778103025 1.0 1.0 21 P67809,Q05086,Q00013,P52597,P31943,Q03518,P35637 7 |
| Phosphoinositides metabolism 0.508368886124927 0.8509007746481971 0.3948244745103382 1.0 1.0 7 Q8NEB9 1 |
| Vitamin a and carotenoid metabolism 0.6883473107198379 0.8430419088718071 0.3992050056679437 1.0 1.0 3 Q8WTV0 1 |
| Glutathione metabolism 0.5565441312573819 0.8401781348194656 0.4008085160053243 1.0 1.0 5 O75874 1 |
| Relationship between inflammation cox2 and egfr 0.5692951464359364 0.8127819035888316 0.4163431127128638 1.0 1.0 4 Q9H7Z7 1 |
| Epo receptor signaling 0.4977958930374058 0.7984643478763446 0.4246010744639112 1.0 1.0 7 P51692 1 |
| Network map of sarscov2 signaling pathway 0.4426687240907858 0.7897868795496695 0.4296522427585993 1.0 1.0 27 Q9P253,P06493,Q7Z434,Q14240,Q96J02,O95067,Q08380,Q99829,P07858,P06730 10 |
| Nad biosynthetic pathways 0.5421160668082183 0.77626515210552 0.4375924443266792 1.0 1.0 5 P43490 1 |
| Ccl18 signaling pathway 0.4362589649639545 0.7632980775071133 0.4452856483677578 1.0 1.0 11 Q86UE4,P07196,P08670 3 |
| Factors and pathways affecting insulinlike growth factor igf1akt signaling 0.4839141355721122 0.7302259122889534 0.4652521060134309 1.0 1.0 7 P49770,P06730,Q13418 3 |
| Fluoropyrimidine activity 0.4194622343047043 0.717181499644025 0.4732621130218719 1.0 1.0 12 Q92820,Q9BZX2,Q06203,P00374 4 |
| Amyotrophic lateral sclerosis als 0.438591362275905 0.6859138588161889 0.4927674303236573 1.0 1.0 9 P07196,Q9BUN8 2 |
| Il7 signaling pathway 0.4699534742120291 0.6624819011754122 0.507662430228979 1.0 1.0 7 P51692,P28482,P49841,O00459 4 |
| Inhibition of exosome biogenesis and secretion by manumycin a in crpc cells 0.4324021799168706 0.6526791539836584 0.5139631443010049 1.0 1.0 9 P61020,P31943 2 |
| Mitochondrial complex iv assembly 0.383689539078308 0.6516820459903984 0.5146063071383011 1.0 1.0 16 Q7KZN9,P13073,P14406,Q9Y2R0 4 |
| Nsp1 from sarscov2 inhibits translation initiation in the host cell 0.3990578339509982 0.6496156524960706 0.5159405198605422 1.0 1.0 13 P05198,P55010,O75822,O15372,O00303,P60228 6 |
| Camkk2 pathway 0.4095202710165776 0.6108336192451528 0.5413097341452917 1.0 1.0 11 P09601 1 |
| 1q211 copy number variation syndrome 0.4114949128543466 0.5795156589628471 0.562241283832758 1.0 1.0 10 Q16625,Q9NPH0 2 |
| Biomarkers for pyrimidine metabolism disorders 0.4524242908111231 0.5790287602433642 0.5625697673390899 1.0 1.0 7 Q9H0P0,Q9Y606,P31350 3 |
| Apoptosis 0.3947526899425224 0.5731768286826168 0.5665249716834229 1.0 1.0 12 P08069,Q07812,P55210,Q07820,Q9NR28 5 |
| Familial hyperlipidemia type 3 0.7879746835443029 0.5721960544860875 0.5671891601845802 1.0 1.0 2 Q8WTV0 1 |
| Familial hyperlipidemia type 1 0.7879746835443028 0.5721960544860868 0.5671891601845807 1.0 1.0 2 Q9UBV2 1 |
| Familial hyperlipidemia type 5 0.7879746835443028 0.5721960544860868 0.5671891601845807 1.0 1.0 2 Q9UBV2 1 |
| Influence of laminopathies on wnt signaling 0.400212256677752 0.5589969926923594 0.5761637725918201 1.0 1.0 11 O60725 1 |
| S1p receptor signal transduction 0.4458238550158181 0.5481644807994446 0.583578968626802 1.0 1.0 7 Q13510 1 |
| Il17 signaling pathway 0.5044331855604653 0.5457007233551722 0.585271674632974 1.0 1.0 4 P28482,P40763,P49841 3 |
| Copper homeostasis 0.4114362094710575 0.5420939504116569 0.5877537860113666 1.0 1.0 9 P05067 1 |
| Statin inhibition of cholesterol production 0.4871126605076589 0.5418018807654355 0.5879549956135235 1.0 1.0 5 Q8WTV0,P01130 2 |
| Mapk cascade 0.5866630113033796 0.4821765552377652 0.6296805300604309 1.0 1.0 3 P62993 1 |
| Tcell receptor tcr signaling pathway 0.3703520548163443 0.4805506651372109 0.6308358860587446 1.0 1.0 13 P46108,Q9UJU6,P62993,P08670,Q13153 5 |
| Glycerophospholipid biosynthetic pathway 0.4047312567029243 0.4764782333131203 0.6337337108868866 1.0 1.0 8 Q9HCL2,O00116,Q9BTU6 3 |
| Riboflavin and coq disorders 0.4517853134994673 0.4619814598441393 0.6440946160053163 1.0 1.0 6 O75208 1 |
| Proteasome degradation 0.4278399365676869 0.4509785416786507 0.6520050146966787 1.0 1.0 40 P49721,P61289,P60900,P20618,P28070,P62195,P10321,P51665,P28072,O00231,Q99436,P28074,Q9UL46 13 |
| Tnfalpha signaling pathway 0.3568393076882582 0.4403792361361023 0.6596624609755799 1.0 1.0 18 Q16543,Q9NR28 2 |
| Ebsteinbarr virus lmp1 signaling 0.5615701171256668 0.4031360722897283 0.6868481251593828 1.0 1.0 3 P28482,P07900 2 |
| Translation factors 0.3967133808563978 0.3727332073834616 0.7093470186958135 1.0 1.0 34 P05198,P23588,O75153,Q13347,Q14240,P55010,P29692,P11940,O75822,O15372,P49770,O00303,P06730,P60228 14 |
| Intracellular trafficking proteins involved in cmt neuropathy 0.3759071726227579 0.3645803854568292 0.7154246586394202 1.0 1.0 9 P07196,Q9UI14,P50570 3 |
| Regulation of apoptosis by parathyroid hormonerelated protein 0.4201593331140096 0.3374936711919597 0.7357447822488521 1.0 1.0 6 Q07820,Q9BXK5,P49841 3 |
| Pentose phosphate metabolism 0.4253037738169495 0.3078090553151167 0.7582276307773788 1.0 1.0 5 P52209 1 |
| Nucleotidebinding oligomerization domain nod pathway 0.3899539999169465 0.3043414656252461 0.7608677574537475 1.0 1.0 7 Q13685,Q9P0J0 2 |
| Glucocorticoid receptor pathway 0.4096728223569258 0.298909545926276 0.7650090633174658 1.0 1.0 6 P27105 1 |
| Autophagy 0.3650754422895366 0.290938192948643 0.7710985903933356 1.0 1.0 8 Q8NEB9,Q9Y4P8 2 |
| Pdgfrbeta pathway 0.4040098515103901 0.2787091661287676 0.7804680275968665 1.0 1.0 6 P51692 1 |
| Disorders of folate metabolism and transport 0.3615544440924187 0.2755852561062281 0.7828666352229843 1.0 1.0 8 Q99707,P00374,P34897 3 |
| Kallmann syndrome 0.5158680435840503 0.2742954367808313 0.7838575910071468 1.0 1.0 3 P62993 1 |
| Genes controlling nephrogenesis 0.4005255900687491 0.2665132681454025 0.7898439423140025 1.0 1.0 6 Q13418 1 |
| Cysteine and methionine catabolism 0.4120406243152728 0.2636014287121496 0.7920870575028833 1.0 1.0 5 P25325 1 |
| Glycogen synthesis and degradation 0.3235688000174318 0.251754840411247 0.8012305652954175 1.0 1.0 18 P06737,P52789,P46976,P30154,P49841,P63151,P30153,P36871 8 |
| Regulation of wnt bcatenin signaling by small molecule compounds 0.4183027232425526 0.2463563723850104 0.8054063753949774 1.0 1.0 4 O14641,P35222,P49841 3 |
| Embryonic stem cell pluripotency pathways 0.3446909304508008 0.245801071912823 0.8058362272495663 1.0 1.0 10 O14641,P62993,P28482,P49841,O00459,P61160 6 |
| Nrf2 pathway 0.3257690187117611 0.2456386520219565 0.8059619657581751 1.0 1.0 19 P11413,P52209,P09601 3 |
| Tca cycle nutrient use and invasiveness of ovarian cancer 0.5042735042734974 0.2451940527199269 0.8063061811079364 1.0 1.0 3 P28482,P40763 2 |
| Rac1pak1p38mmp2 pathway 0.3178261334845466 0.2393294052624295 0.8108501657267146 1.0 1.0 17 P46108,P62993,P43246,P55210,P16949,P51692,Q13153 7 |
| Wntbetacatenin signaling pathway in leukemia 0.4116529449018343 0.2271879234835631 0.8202776178596582 1.0 1.0 4 P48729,P35222,P49841 3 |
| Metabolic pathway of ldl hdl and tg including diseases 0.4941127608323629 0.2210010007223759 0.8250916537800368 1.0 1.0 3 Q8WTV0 1 |
| Nephrotic syndrome 0.3115735214012136 0.2056951442663667 0.8370290517711054 1.0 1.0 14 P11047,O43707,Q14108,O75844 4 |
| Map3k1 role in promoting and blocking gonadal determination 0.3802934960088451 0.1687548533413007 0.865989470727867 1.0 1.0 5 P49841,Q13464 2 |
| Proximal tubule transport 0.3213123864216456 0.1676087808736709 0.8668910627940032 1.0 1.0 11 P08183 1 |
| Gdnfret signaling axis 0.464704020259568 0.1582268436158188 0.8742780520402764 1.0 1.0 3 P35222,O94813 2 |
| Cannabinoid receptor signaling 0.3752803760616083 0.1553164432474068 0.8765718530803335 1.0 1.0 5 Q8NCG7 1 |
| Vitamin b12 metabolism 0.3486502014236639 0.1529270198843352 0.8784558277426702 1.0 1.0 7 Q99707,Q8WTV0,P34897,P01130 4 |
| Heart development 0.458689458689452 0.1467586009979926 0.8833225623989998 1.0 1.0 3 P35222,P28482 2 |
| Photodynamic therapyinduced ap1 survival signaling 0.356780735107725 0.1303156954278573 0.8963166628028962 1.0 1.0 6 Q07812,P07900,P20248,Q07820,P49327 5 |
| Burn wound healing 0.3195168957531807 0.1242511457748645 0.9011164274812624 1.0 1.0 9 P08670 1 |
| Bladder cancer 0.3566677225213852 0.109352827996466 0.9129226471002057 1.0 1.0 5 P28482,P11802,P12931,O00459 4 |
| Cytosine methylation 0.3550558055764907 0.1056698141522284 0.9158443310436876 1.0 1.0 5 O75874 1 |
| Thymic stromal lymphopoietin tslp signaling pathway 0.3039908593950992 0.0989896819600626 0.921146462468906 1.0 1.0 11 Q9BTU6 1 |
| Unfolded protein response 0.3565547815072846 0.0960519649603867 0.9234793012446096 1.0 1.0 4 P05198,P42575,Q9Y3I0 3 |
| Notch signaling 0.3270998415214003 0.0870608533951105 0.9306231416574988 1.0 1.0 7 O14641,Q13363,Q92542,Q06330,Q92769,Q13547 6 |
| Apoptosisrelated network due to altered notch3 in ovarian cancer 0.2905228552049227 0.086016957813431 0.9314529368025126 1.0 1.0 13 P08670 1 |
| T cell receptor and costimulatory signaling 0.4175371953149707 0.0810011507566306 0.9354410373423364 1.0 1.0 3 P48729,P49841 2 |
| Canonical and noncanonical notch signaling 0.556012658227846 0.0798836446910982 0.9363297978999556 1.0 1.0 2 Q06330 1 |
| Angiotensin ii receptor type 1 pathway 0.4165875276986375 0.0797428255832778 0.9364417979943108 1.0 1.0 3 Q06124,P28482 2 |
| Serotonin receptor 2 and elksrfgata4 signaling 0.4058246280468477 0.0662741572014649 0.947159557545218 1.0 1.0 3 P27361,P28482 2 |
| Somatroph axis gh and its relationship to dietary restriction and aging 0.3965257345189633 0.0557859520642214 0.9555123261448129 1.0 1.0 3 P08069 1 |
| Tcell activation sarscov2 0.3008010115564422 0.0505381352423355 0.959693560688623 1.0 1.0 8 P28482,P62993,P49841,Q15382 4 |
| Joubert syndrome 0.2766567684601264 0.0497728884042038 0.9603033718156142 1.0 1.0 17 O43924 1 |
| Leptininsulin signaling overlap 0.518670886075947 0.0493055364022539 0.9606758074751168 1.0 1.0 2 P40763 1 |
| Synaptic signaling pathways associated with autism spectrum disorder 0.2937817258883178 0.0491863703927887 0.9607707729708936 1.0 1.0 10 P27361,Q05086,Q15334,P54619,Q13131,P28482,P49841,Q15382,O00459 9 |
| Bdnftrkb signaling 0.3208047786578079 0.0449696209994884 0.964131523378248 1.0 1.0 6 Q15418,P62993,Q15382 3 |
| Resistin as a regulator of inflammation 0.5041139240506305 0.0404619332360673 0.9677248550502078 1.0 1.0 2 P28482 1 |
| Serotonin receptor 467 and nr3c signaling 0.5041139240506305 0.0404619332360673 0.9677248550502078 1.0 1.0 2 P28482 1 |
| Neovascularisation processes 0.5041139240506305 0.0404619332360673 0.9677248550502078 1.0 1.0 2 P28482 1 |
| 3q29 copy number variation syndrome 0.2726867807517349 0.0390292930911893 0.9688670338911908 1.0 1.0 14 P61088,Q12959,O95684,P55210,Q96EB6,P51692 6 |
| Folatealcohol and cancer pathway hypotheses 0.4699367088607568 0.0252933955677981 0.9798209418208964 1.0 1.0 2 Q99707 1 |
| Cancer immunotherapy by ctla4 blockade 0.4585443037974656 0.0217055680841298 0.9826828221314272 1.0 1.0 2 O00459 1 |
| Cancer immunotherapy by pd1 blockade 0.4585443037974656 0.0217055680841298 0.9826828221314272 1.0 1.0 2 P40763 1 |
| Nanoparticlemediated activation of receptor signaling 0.3091542603737771 0.021055344218175 0.9832015071407952 1.0 1.0 5 P28482,P62993,Q9Y490,P12931 4 |
| Development of ureteric collection system 0.3091542603737768 0.0210553442181744 0.9832015071407956 1.0 1.0 5 P35222,Q5SZK8,Q13418,O94813 4 |
| Pkcgamma calcium signaling pathway in ataxia 0.4056962025316426 0.0118313321180491 0.9905601830013822 1.0 1.0 2 P23634 1 |
| Notch signaling pathway 0.2648433492312654 0.0116700409499374 0.9906888658495904 1.0 1.0 14 Q96J02,P63208 2 |
| Pi3kaktmtor signaling pathway and therapeutic opportunities 0.2932235592146961 0.008783702626791 0.9929917094064608 1.0 1.0 4 O00459,P49841,Q15382 3 |
| Microrna network associated with chronic lymphocytic leukemia 0.3563291139240475 0.0086550595555681 0.9930943478250224 1.0 1.0 2 Q07820 1 |
| Mirna regulation of prostate cancer signaling pathways 0.2935023771790871 0.0050499207921226 0.9959707632920928 1.0 1.0 7 P62993,P35222,P28482,P04637,P49841,Q8NCF5 6 |
| Regulatory circuits of the stat3 signaling pathway 0.293502377179086 0.0050499207921206 0.9959707632920944 1.0 1.0 7 P27361,P12931,P28482,P40763,P16949,Q13263 6 |
| Vasopressinregulated water reabsorption 0.2607686945061369 0.0039541106679292 0.9968450843675352 1.0 1.0 16 Q12846,Q13409 2 |
|
|
